mRNA Platform Global Strategic Research Report 2024
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report delves into the mRNA platform, examining its global competitive landscape and the market presence of key players. It provides a conceptual understanding of mRNA, highlighting its revolutionary approach to medicine and the significant scientific breakthroughs it represents. The introduction of mRNA vaccines is explored, emphasizing their unprecedented turnaround time and ability to transform cells into vaccine factories.
Advantages and disadvantages of mRNA vaccines are discussed, along with comparisons between Pfizer, Moderna, and AstraZeneca COVID-19 vaccines. The report outlines the differences in development processes between traditional and mRNA vaccines, elucidating how mRNA vaccines work and their safety quotient.
It also discusses notable efforts centered on mRNA technology and addresses the challenges involved, positioning mRNA as a serious candidate deserving attention from the scientific community.
MARKET OVERVIEW
mRNA Platform - Global Key Competitors Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
MRNA - A CONCEPTUAL UNDERSTANDING
MRNA: A New Approach to Medicine
Long Wait & Scientific Breakthroughs
mRNA Vaccines - An Introduction
With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development
mRNA: Making Cells Act as Vaccine Factory
mRNA Vaccines: Advantages
mRNA Vaccines: Cons
mRNA Vaccine Approvals
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
Traditional Vs. mRNA Vaccines: Key Differences
Traditional Vs. mRNA Vaccines: The Development Process
How mRNA Vaccine Works & Earlier Testing Efforts
mRNA Vaccines: Safety Quotient
Other NoTable Efforts Centered on mRNA Technology
Overcoming Challenges
As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community
GLOBAL MARKET OVERVIEW
Global mRNA Vaccines Market on a Dynamic Growth Track
mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market
The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations
RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE
Pfizer and BioNTech's COVID-19 Vaccine Receives World's First Authorization
UK Clinches the First Position in the World to Approve Pfizer's Vaccine
After UK, US Gives Nod to Pfizer's Vaccine
EU Approves Pfizer's Vaccine
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
Moderna's mRNA Vaccine Bags Approval from US FDA
Moderna Kick-Starts Inoculation in the US
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
Recent Market Activity
COMPETITIVE SCENARIO
BioNTech - A Pioneer in mRNA-based Vaccines and Therapies
List of BioNTech's mRNA Candidates in Clinical Trials for Cancer
Moderna's Ambitious Stride into Vaccine Development: From a Novice to Know All
Moderna's mRNA Prophylactic Vaccines
mRNA Cancer Vaccines
mRNA Intratumoral Immuno-Oncology
mRNA Systemic Secreted & Cell Surface Therapeutics
mRNA Systemic Intracellular Therapeutics
Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19
mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon
Noteworthy Startups Exploiting mRNA Technology
Providence Therapeutics
pHion Therapeutics
eTheRNA immunotherapies & 20Med Therapeutics
MARKET TRENDS & DRIVERS
Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead
mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum
Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Increasing Healthcare Expenditure to Foster Market Growth
Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
Regulatory Landscape for mRNA Vaccines
Regulatory Pathway Dealing with mRNA Vaccines
mRNA Vaccine Patent Scenario
The Best Route of Administration for mRNA Vaccines
mRNA CANCER VACCINES
Introduction
Cancer Vaccines Vs. Immunotherapies
Clinical Trials of mRNA Encoding Immunostimulants
mRNA Vaccines Vs. DNA Vaccines
Clinical Trials of mRNA Encoding TAAs
mRNA Vaccines Vs. Other Vaccines
Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag)
mRNA Benefits Profile
mRNA Vaccines for Covid-19 Pave the Way
Challenges
Personalized mRNA Vaccine
Clinical Overview of mRNA Cancer Vaccines
mRNA encoding Immunostimulants
mRNA vaccine encoding tumor-associated antigens
mRNA vaccine encoding Neoantigen, personalized vaccine
mRNA Influenza Vaccines
Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform
Vaccines Built on mRNA
Clinical Trials for mRNA Vaccines
mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts
mRNA: A Next-Generation Vaccination Approach
Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses
COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots
mRNA Vaccines Vs. Other Flu Shots
mRNA Technology, H/N Spike Proteins & Clinical Trials
mRNA Technology: A SuiTable Candidate for Universal & Effective Influenza Vaccines
Benefits & Limitations of mRNA Vaccines over Traditional Options
FOCUS ON SELECT PLAYERS(Total 96 Featured)
AstraZeneca PLC
Asuragen, Inc.
Catalent Pharma Solutions
Altogen Labs
Arcturus Therapeutics, Inc.
BioNTech AG
CRISPR Therapeutics
Aldevron
AKESOgen, Inc.
baseclick GmbH
chimeron bio
Acuitas Therapeutics
Accent Therapeutics
Accanis Biotech F&E GmbH & Co KG
Avectas
For more information about this report visit https://www.researchandmarkets.com/r/e1uos1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900